Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 222-227

  Cuesta, Manuel J ^a   García de Jalón, Elena ^a   Campos, Maria S ^a   Ibáñez, Berta ^b   Sánchez Torres, Ana M ^a   Peralta, Víctor ^a  

^a Universidad Pública de Navarra   (Spain)

^b Fundacion Miguel Servet   (Spain)

Author keywords

Cognition; Duration of untreated psychosis (DUP); First episode psychosis; Longitudinal study

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; BRIEF PSYCHOTIC DISORDER; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; DELUSIONAL DISORDER; DISEASE ASSOCIATION; DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; REACTION TIME; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SYMPTOM ONSET IN SCHIZOPHRENIA; SYMPTOMATOLOGY; TASK PERFORMANCE; VERBAL MEMORY; VISION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84866888112     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.019     Document Type: Article

References (43)

1. Addington J., Van Mastrigt S., Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol. Med. 2004, 34(2):277-284.
2. Addington J., Saeedi H., Addington D. The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophr. Res. 2005, 78(1):35-43.
3. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49(8):615-623.
4. APA DSM-IV-TR. Diagnostic and Statistical Manual of Mental Disorders. Text Revision 2000, American Psychiatric Association, Washington. Fourth Edition.
5. Barnes T.R., Leeson V.C., Mutsatsa S.H., Watt H.C., Hutton S.B., Joyce E.M. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br. J. Psychiatry 2008, 193(3):203-209.
6. Birchwood M., Todd P., Jackson C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry 1998, 172(33):53-59. (Suppl.).
7. Compton M.T., Gordon T.L., Weiss P.S., Walker E.F. The "doses" of initial, untreated hallucinations and delusions: a proof-of-concept study of enhanced predictors of first-episode symptomatology and functioning relative to duration of untreated psychosis. J. Clin. Psychiatry 2011, 72(11):1487-1493.
8. Crespo-Facorro B., Rodriguez-Sanchez J.M., Perez-Iglesias R., Mata I., Ayesa R., Ramirez-Bonilla M., Martinez-Garcia O., Vazquez-Barquero J.L. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J. Clin. Psychiatry 2009, 70(5):717-729.
9. Cuesta M.J., García de Jalon E., Campos M.S., Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br. J. Psychiatry 2009, 194(5):439-445.
10. Drake R.J., Haley C.J., Akhtar S., Lewis S.W. Causes and consequences of duration of untreated psychosis in schizophrenia. Br. J. Psychiatry 2000, 177:511-515.
11. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64(10):1115-1122.
12. Goldberg T.E., Burdick K.E., McCormack J., Napolitano B., Patel R.C., Sevy S.M., Goldman R., Lencz T., Malhotra A.K., Kane J.M., Robinson D.G. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr. Res. 2009, 107(2-3):262-266.
13. Gurpegui M., Alvarez E., Bousono M., Ciudad A., Carlos Gomez J., Olivares J.M. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. Eur. Neuropsychopharmacol. 2007, 17(11):725-734.
14. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
15. Hoff A.L., Sakuma M., Wieneke M., Horon R., Kushner M., DeLisi L.E. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am. J. Psychiatry 1999, 156(9):1336-1341.
16. Lappin J.M., Morgan K., Morgan C., Hutchison G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Jones P.B., Leff J., Murray R.M., Dazzan P. Gray matter abnormalities associated with duration of untreated psychosis. Schizophr. Res. 2006, 83(2-3):145-153.
17. Leeson V.C., Barnes T.R., Harrison M., Matheson E., Harrison I., Mutsatsa S.H., Ron M.A., Joyce E.M. The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. Schizophr. Bull. 2010, 36(2):400-409.
18. Lewandowski K.E., Cohen B.M., Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol. Med. 2011, 41(2):225-241.
19. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50(5):369-376.
20. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry 1996, 57(Suppl. 9):5-9.
21. Loebel A.D., Lieberman J.A., Alvir J.M., Mayerhoff D.I., Geisler S.H., Szymanski S.R. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry 1992, 149(9):1183-1188.
22. Malla A.K., Bodnar M., Joober R., Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr. Res. 2011, 125(1):13-20.
23. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 2005, 62(9):975-983.
24. McGlashan T.H. Is active psychosis neurotoxic?. Schizophr. Bull. 2006, 32(4):609-613.
25. McGorry P.D., Edwards J., Mihalopoulos C., Harrigan S.M., Jackson H.J. EPPIC: an evolving system of early detection and optimal management. Schizophr. Bull. 1996, 22(2):305-326.
26. Naqvi H.A., Hussain S., Zaman M., Islam M. Pathways to care: duration of untreated psychosis from Karachi, Pakistan. PLoS One 2009, 4(10):e7409.
27. Norman R.M., Malla A.K., Manchanda R. Early premorbid adjustment as a moderator of the impact of duration of untreated psychosis. Schizophr. Res. 2007, 95(1-3):111-114.
28. Penn D.L., van der Does A.J., Spaulding W.D., Garbin C.P., Linszen D., Dingemans P. Information processing and social cognitive problem solving in schizophrenia. Assessment of interrelationships and changes over time. J. Nerv. Ment. Dis. 1993, 181(1):13-20.
29. Peralta V., Cuesta M.J., Martinez-Larrea A., Serrano J.F., Langarica M. Duration of untreated psychotic illness: the role of premorbid social support networks. Soc Psychiatry Psychiatr. Epidemiol. 2005, 40(5):345-349.
30. Perkins D.O., Leserman J., Jarskog L.F., Graham K., Kazmer J., Lieberman J.A. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr. Res. 2000, 44(1):1-10.
31. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162(10):1785-1804.
32. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., Bromet E. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2009, 35(5):1022-1029.
33. Reitan R., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and clinical interpretation 1993, Neuropsychology Press, Tucson, AZ.
34. Rund B.R., Melle I., Friis S., Johannessen J.O., Larsen T.K., Midbøe L.J., Opjordsmoen S., Simonsen E., Vaglum P., McGlashan T. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 2007, 91(1-3):132-140.
35. Sole B., Bonnin C.M., Torrent C., Martinez-Aran A., Popovic D., Tabares-Seisdedos R., Vieta E. Neurocognitive impairment across the bipolar spectrum. CNS Neurosci. Ther. 2012, 18(3):194-200.
36. Spaulding W., Garbin C.P., Dras S.R. Cognitive abnormalities in schizophrenic patients and schizotypal college students. J. Nerv. Ment. Dis. 1989, 177(12):717-728.
37. Toulopoulou T., Murray R.M. Verbal memory deficit in patients with schizophrenia: an important future target for treatment. Expert. Rev. Neurother. 2004, 4(1):43-52.
38. Townsend L.A., Norman R.M. Course of cognitive functioning in first episode schizophrenia spectrum disorders. Expert. Rev. Neurother. 2004, 4(1):61-68.
39. Townsend L.A., Norman R.M., Malla A.K., Rychlo A.D., Ahmed R.R. Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. Psychiatry Res. 2002, 113(1-2):69-81.
40. Verdoux H., Liraud F., Bergey C., Assens F., Abalan F., van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr. Res. 2001, 49(3):231-241.
41. Wechsler D. A standardized memory scale for clinical use. J. Psychol. 1945, 19(1):87-95.
42. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8(3):457-472.
43. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 1991, 17(2):325-351.